Dystonia involves a lack of synergy of antagonist and agonist muscles, resulting in irregular and unco-ordinated movements.
U S N E U R O L O G Y
Secondary dystonia may arise from trauma, overuse, and/or medications. 14 Tardive dystonia present similarly to idiopathic CD. 15 While the newer antipsychotic medications are said to have less chance of iatrogenic movement disorders, tardive dystonia remains an issue with all medications that block dopamine. The use of metoclopramide for nausea remains a risk factor for developing tardive syndromes. 16 Additionally, patients may experience minor or major trauma to the neck, acting as a precipitant to CD. 17 The role of trauma in the development of CD is less clear than the role of overuse in musicians or other occupational dystonia. 18 Regardless of the etiology of CD, the treatment remains the same as idiopathic CD.
Treatment

Oral Medications
The treatment of CD includes oral medications, such as anticholinergics and benzodiazepines, and antispasmodics, such as baclofen. The efficacy of oral medications in focal dystonia is limited. Only one study compared BoNT with oral medications (trihexyphenidyl). 19 BoNT injections provided more efficacy and fewer side effects than oral trihexyphenidyl in patients with comparable CD. While a wide variety of other oral medications has been used, only trihexyphenidyl has been studied in a large clinical trial.
Levetiracetam has been studied in at least two open label trials and both demonstrated no improvement.
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Botulinum Toxin for Cervical Dystonia
The accepted first-line therapy for CD is intramuscular injection of botulinum toxin. A recent report by the American Academy of Neurology (AAN) panel of experts noted that BoNT should be first-line treatment for CD. 22 The Production within a serotype varies by manufacturer, and therefore no generic equivalent is available for these toxins. Thus, trade names will be used to clarify which formulation is being discussed (see Table 1 ). 27 Botox is currently approved in CD, strabismus, facial injections, and medically refractory hyperhidrosis.
Use of Botulinum
The largest trial of BoNTA studied 170 subjects with CD at 21 centers and is detailed in the package insert. 28, 29 This trial has been referred to in reviews of CD treatment, but the study itself has not been published in its entirety in a peer-reviewed publication. The study included only patients with a good response to previous Botox injections. Using a 3D measurement tool to gauge degree of turn, tilt, or other postures, the physicians followed the change in patients treated with active Botox or placebo. 30 In an enriched sample of only In a similarly sized multicenter dose escalation, 75 patients were randomly assigned to receive treatment with placebo or total doses of 250, 500, or 1,000 Dysport units divided between two muscles. Those treated with 500 or 1,000 units demonstrated significant changes in the modified Tsui score at week four versus placebo (p<0.05). The 1,000-unit dose was found to be more effective, but was associated with an increased risk for side effects. The authors noted that because of neck weakness and voice changes, the starting dose should be 500 units. The most common AEs were dry mouth (21, 18, and 33 with 250, 500, and 1,000 units, respectively), neck muscle weakness (11, 12 , and 56% with 250, 500, and 1,000 units, respectively), and dysphagia (21, 29, and 39% with 250, 500, and 1,000 units, respectively).
Botulinum Toxin Serotype A Formulated as Xeomin ®
The newest BoNTA on the market is Xeomin. It is described as a purified, freeze-dried form of BoNT, and is reportedly free from completing proteins. 34 There is no generic form of BoNT.
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In a large, multicenter trial comparing BoNTB with BoNTA (Botox), 139
BoNTA-responsive patients with CD were randomized to receive either product. 35 Comella et al. reported no difference in the improvement noted in the TWSTRS total score at week four. As noted with placebo-controlled trials of BoNTB, 36 the frequency and severity of dysphagia and dry mouth were significantly greater with Myobloc (dysphagia: BOTOX 19% versus Myobloc 48%; dry mouth: BOTOX 41% versus Myobloc 80%). In those benefiting from either drug, the BoNTA-treated group had a modestly longer duration of benefit (Botox 14 weeks, Myobloc 12.1 weeks; p=0.033).
Recently, Myobloc was compared with Botox in a large, randomized, clinical trial of toxin-naïve patients suffering from CD. 37 The patients in Comella et al., discussed above, all had prior exposure to Botox but not Myobloc. As with other similar trials, the change in the TWSTRS total score at week four was the primary efficacy outcome. Of the 111 toxin-naïve patients participating, similar improvement in TWSTRS total scores was seen in both groups after four weeks. In this study the median duration of effect of BoNTA and BoNTB did not differ and there were no significant differences in the occurrence of injection site pain and dysphagia. As noted in all other studies with BoNTB, dry mouth was more frequently reported.
Frequency of Treatment
The recommended frequency of treatment with BoNT stems from studies of antibody formation. Most physicians treat patients no more than every three months based on concerns for antibody formation with more frequent, high-dose injections. The theory proposed is that higher dose and more frequent injections have the potential to immunize a patient to the protein in the neurotoxin complex. Some studies have used an enzyme-linked immunosorbent assay (ELISA), which measures antibodies, but the ability to measure antibodies that specifically block the activity of the toxin has become more of a focus. 38, 39 The gold standard for measurement of blocking antibodies remains the mouse protection assay. 40 Early studies reported that antibody formation is associated with more frequent and higher doses of BoNT. 40 Early reports of with BoNTA (Dysport and Botox) in CD suggested that the incidence of neutralizing antibodies ranged from 4 to 17% depending on the formulation used. 41 More recently, a newer formulation
were all predictors of worse health-related QOL. After treatment with BoNTA, improvements were noted in all areas of the SF-36, a visual analog scale, TWSTRS, and the Montgomery-Asberg Depression Rating Scale (MADRS). 55 While patients improved, the TWSTRS results did not correlate with any of the SF-36 subscores, suggesting a benefit to including QOL scales in large trials. 54 Likewise, in a study of QOL in patients with focal dystonia (blepharospasm, CD, writers cramp), depression and anxiety were the most important predictors of poorer health-related QOL in all three forms of dystonia. 55 One of the few studies to look at CD treatment with BoNT and employment status in 62 CD patients (patients were between 31 and 66 years of age and had been treated for a median of five years) found that the employment rate fell from 84% at the onset of CD to 47% before the initiation of BoNT treatment. With long-term BoNT treatment, 72% of those who worked at the initiation of treatment remained employed, and 67% of those on sick leave returned to work. The younger patients and those with a higher premorbid education status were more likely to return to work.
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Conclusion
The diagnosis of CD is based on clinical presentation. 
